Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 566

1.

Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).

Testori A, De Salvo GL, Montesco MC, Trifirò G, Mocellin S, Landi G, Macripò G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Soteldo J, Casara D, Schiavon M, Vecchiato A, Pasquali S, Baldini F, Mazzarol G, Rossi CR; Italian Melanoma Intergroup..

Ann Surg Oncol. 2009 Jul;16(7):2018-27. doi: 10.1245/s10434-008-0273-8.

PMID:
19132446
2.

Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.

Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W.

Ann Surg Oncol. 2006 Dec;13(12):1655-63.

PMID:
17016755
3.

The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, van Diest PJ, Pijpers R, Ferwerda CC, Vuylsteke RJ, Meijer S.

Cancer. 2001 Jun 15;91(12):2401-8.

PMID:
11413531
4.

Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.

Rossi CR, De Salvo GL, Bonandini E, Mocellin S, Foletto M, Pasquali S, Pilati P, Lise M, Nitti D, Rizzo E, Montesco MC.

Ann Surg Oncol. 2008 Apr;15(4):1202-10. doi: 10.1245/s10434-007-9734-8. Erratum in: Ann Surg Oncol. 2008 May;15(5):1552.

PMID:
18165880
5.

Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.

Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G, Wolff K, Pehamberger H, Diem E.

Br J Cancer. 2005 Feb 28;92(4):662-7.

6.

Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.

Scoggins CR, Martin RC, Ross MI, Edwards MJ, Reintgen DS, Urist MM, Gershenwald JE, Sussman JJ, Dirk Noyes R, Goydos JS, Beitsch PD, Ariyan S, Stromberg AJ, Hagendoorn LJ, McMasters KM.

Ann Surg Oncol. 2010 Mar;17(3):709-17. doi: 10.1245/s10434-009-0858-x.

PMID:
19967459
7.

Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma.

Ghaferi AA, Wong SL, Johnson TM, Lowe L, Chang AE, Cimmino VM, Bradford CR, Rees RS, Sabel MS.

Ann Surg Oncol. 2009 Nov;16(11):2978-84. doi: 10.1245/s10434-009-0665-4.

PMID:
19711133
8.

Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.

Sabel MS, Griffith K, Sondak VK, Lowe L, Schwartz JL, Cimmino VM, Chang AE, Rees RS, Bradford CR, Johnson TM.

J Am Coll Surg. 2005 Jul;201(1):37-47.

PMID:
15978442
9.

The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI).

Rossi CR, De Salvo GL, Trifirò G, Mocellin S, Landi G, Macripò G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Montesco MC, Casara D, Schiavon M, Foletto M, Baldini F, Testori A.

J Nucl Med. 2006 Feb;47(2):234-41.

10.

Regional recurrence after negative sentinel lymph node biopsy for melanoma.

Carlson GW, Page AJ, Cohen C, Parker D, Yaar R, Li A, Hestley A, Delman KA, Murray DR.

Ann Surg. 2008 Sep;248(3):378-86. doi: 10.1097/SLA.0b013e3181855718.

PMID:
18791358
11.

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C.

Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034.

PMID:
19553103
12.

Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.

Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF.

J Am Acad Dermatol. 2001 May;44(5):762-6.

PMID:
11312421
13.

Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.

Wagner JD, Gordon MS, Chuang TY, Coleman JJ 3rd, Hayes JT, Jung SH, Love C.

Cancer. 2000 Jul 15;89(2):453-62.

PMID:
10918179
14.

Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.

Gershenwald JE, Mansfield PF, Lee JE, Ross MI.

Ann Surg Oncol. 2000 Mar;7(2):160-5.

PMID:
10761797
15.

Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?

Mays MP, Martin RC, Burton A, Ginter B, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Stromberg AJ, McMasters KM, Scoggins CR.

Cancer. 2010 Mar 15;116(6):1535-44. doi: 10.1002/cncr.24895.

16.

Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.

Debarbieux S, Duru G, Dalle S, Béatrix O, Balme B, Thomas L.

Br J Dermatol. 2007 Jul;157(1):58-67.

PMID:
17501957
17.

Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.

Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M, Ruzicka T, Berking C, Schmid-Wendtner MH.

Melanoma Res. 2010 Aug;20(4):330-7. doi: 10.1097/CMR.0b013e32833ba9ff.

PMID:
20526218
18.

Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.

Roka F, Mastan P, Binder M, Okamoto I, Mittlboeck M, Horvat R, Pehamberger H, Diem E.

Eur J Surg Oncol. 2008 Jan;34(1):82-8.

PMID:
17360144
19.

Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?

Gajdos C, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2009 Dec 15;115(24):5752-60. doi: 10.1002/cncr.24660.

20.

Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

Macripò G, Quaglino P, Caliendo V, Ronco AM, Soltani S, Giacone E, Pau S, Fierro MT, Bernengo MG.

Melanoma Res. 2004 Apr;14(2):S9-12.

PMID:
15057050

Supplemental Content

Support Center